Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

45.76
-1.7900-3.76%
Volume:817.94K
Turnover:38.01M
Market Cap:4.39B
PE:-7.07
High:47.83
Open:47.24
Low:45.56
Close:47.55
52wk High:78.48
52wk Low:30.04
Shares:95.99M
Float Shares:90.53M
Volume Ratio:0.79
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4700
EPS(LYR):-6.4700
ROE:-30.18%
ROA:-15.76%
PB:2.29
PE(LYR):-7.07

Loading ...

Stock Track | CRISPR Therapeutics Soars 5.01% Amid M&A Rumor Highlighted in Betaville Blog

Stock Track
·
Nov 18, 2025

Crispr Therapeutics rumor highlighted in Betaville blog

TIPRANKS
·
Nov 18, 2025

Stock Track | CRISPR Therapeutics Soars 6.36% Amid Bullish Options Activity

Stock Track
·
Nov 15, 2025

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Nov 15, 2025

CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results

Simply Wall St.
·
Nov 13, 2025

Press Release: Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Dow Jones
·
Nov 13, 2025

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news
·
Nov 11, 2025

RBC Raises Price Target on CRISPR Therapeutics to $50 From $42, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 11, 2025

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 11, 2025

Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress

TIPRANKS
·
Nov 11, 2025

Merck's Heart Pill Slashes Cholesterol Levels in Test Patients -- Barrons.com

Dow Jones
·
Nov 11, 2025

Crispr Therapeutics price target lowered to $50 from $52 at Clear Street

TIPRANKS
·
Nov 11, 2025

Crispr Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Nov 11, 2025

Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)

TIPRANKS
·
Nov 10, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 10, 2025

CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

Benzinga
·
Nov 10, 2025

Earnings Flash (CRSP) CRISPR Therapeutics Posts Q3 Net Loss $1.17 a Share, vs. FactSet Est of $1.25 Loss

MT Newswires Live
·
Nov 10, 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 10, 2025

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

TIPRANKS
·
Nov 10, 2025

Promising Phase I Results of CTX310 Justify Buy Rating for CRISPR Therapeutics

TIPRANKS
·
Nov 10, 2025